Thus, enhancement of ERBB2-mediated signal in EGFR1-directed antibody (cetuximab) and IGF1R-mediated signal in anti-erbB2/HER2 (trastuzumab) antibody-treated breast cancer patients confers resistance to the treatment (Nahta et al., 2005; Yonesaka et al., 2011). Here, IGF1R is linked to breast carcinoma.